This/DT work/NN introduces/VBZ a/DT method/NN to/TO tune/VB a/DT sequence/NN -/HYPH based/VBN generative/JJ model/NN for/IN molecular/JJ de/FW novo/FW design/NN that/WDT through/IN augmented/VBN episodic/JJ likelihood/NN can/MD learn/VB to/TO generate/VB structures/NNS with/IN certain/JJ specified/VBN desirable/JJ properties/NNS ./.
We/PRP demonstrate/VBP how/WRB this/DT model/NN can/MD execute/VB a/DT range/NN of/IN tasks/NNS such/JJ as/IN generating/VBG analogues/NNS to/IN a/DT query/NN structure/NN and/CC generating/VBG compounds/NNS predicted/VBN to/TO be/VB active/JJ against/IN a/DT biological/JJ target/NN ./.
As/IN a/DT proof/NN of/IN principle/NN ,/, the/DT model/NN is/VBZ first/JJ trained/VBN to/TO generate/VB molecules/NNS that/WDT do/VBP not/RB contain/VB sulphur/NN ./.
As/IN a/DT second/JJ example/NN ,/, the/DT model/NN is/VBZ trained/VBN to/TO generate/VB analogues/NNS to/IN the/DT drug/NN Celecoxib/NNP ,/, a/DT technique/NN that/WDT could/MD be/VB used/VBN for/IN scaffold/NN hopping/VBG or/CC library/NN expansion/NN starting/VBG from/IN a/DT single/JJ molecule/NN ./.
Finally/RB ,/, when/WRB tuning/VBG the/DT model/NN towards/IN generating/VBG compounds/NNS predicted/VBN to/TO be/VB active/JJ against/IN the/DT dopamine/NN receptor/NN D2/NN ,/, the/DT model/NN generates/VBZ structures/NNS of/IN which/WDT more/JJR than/IN 95/CD percent/NN are/VBP predicted/VBN to/TO be/VB active/JJ ,/, including/VBG experimentally/RB confirmed/VBN actives/NNS that/WDT have/VBP not/RB been/VBN included/VBN in/IN either/CC the/DT generative/JJ model/NN nor/CC the/DT activity/NN prediction/NN model/NN ./.
